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Fibrotic diseases have an unclear etiology and poor prognosis. Fluctuations in thyroid 
function may play a role in the development of fibrosis, but evidence is fragmented and 
inconclusive. This systematic review and meta-analysis aimed to investigate the 
association of thyroid function with fibrotic diseases of the liver, heart, and lung, in 
humans. 
Methods 
We searched Pubmed, Medline Ovid, Embase Ovid, and Web-of-Science for studies 
published from inception to 14 June 2019, to identify observational studies that 
investigated the association of thyroid function with fibrosis of the liver, heart, and lung, in 
humans. Study quality was evaluated by Newcastle-Ottawa Scale. The Mantel-Haenszel 
method was used to pool the odds ratios (ORs) of studies investigating the association of 
hypothyroidism with liver fibrosis. 
Results 
Out of 2196 identified articles, 18 studies were included in the systematic review, of which 
11 studies reported on liver fibrosis, 4 on myocardial fibrosis, and 3 on pulmonary fibrosis. 
The population sample size ranged from 36 to 7259 subjects, with median mean age 51 
years (range, 36-69) and median percentage of women 53 (range, 17-100). The risk of bias 
of studies was low to moderate to high. Higher serum thyrotropin and lower thyroid 
hormone levels were generally associated with higher likelihood of fibrosis. Compared to 
euthyroidism, overt and subclinical hypothyroidism were associated with a higher 
likelihood of fibrosis in the liver (6 of 7 studies), heart (3 of 3 studies), and lung (3 of 3 
studies). Based on the results of the 7 studies included in the meta-analysis, overt and 
subclinical hypothyroidism were associated with an increased risk of liver fibrosis (pooled 
OR, 2.81; 95% confidence interval [CI], 1.74-4.53; heterogeneity, I2 31.4%; pooled OR, 2.12; 

















































































































































































































This study suggests that low thyroid function is associated with increased likelihood of 
chronic fibrotic diseases of the liver, heart, and lung. However, the evidence is mainly 
based on cross-sectional data. Prospective studies and randomized clinical trials are 
needed to investigate the potential efficacy of thyroid hormone and its analogues on the 














































































































































































































Fibrotic diseases, including liver cirrhosis, hypertrophic cardiomyopathy, and idiopathic 
pulmonary fibrosis, represent a significant cause of disability and mortality (1-4). The 
development of fibrosis is attributable to a maladaptive response characterized by the 
accumulation of extracellular matrix proteins such as collagen and fibronectin (5). Fibrotic 
elements progressively remodel and destroy the normal tissue architecture, ultimately 
resulting in organ failure. Hence, nonalcoholic steatohepatitis can progress to 
decompensated cirrhosis (6); myocardial fibrosis leads to ventricular diastolic dysfunction 
(7); whereas pulmonary fibrosis contributes to a decline in the lung function (8). 
To date, the prognosis of fibrotic diseases remains poor, owing to the poor understanding 
of its pathogenesis and the lack of effective therapeutic options. Therefore, current 
research is focused on the identification of novel determinants of fibrosis, which could be 
further translated into the development of effective treatments (9-11). Among other 
factors, hypothyroidism has been implicated in the etiology of fibrosis (12-15). Pronounced 
hypothyroidism is typically characterized by an increased production of 
mucopolysaccharides, resulting in interstitial fibrosis and extracellular water retention, 
also known as myxedema (16). Yet, the exact role of thyroid hormones in the development 
of fibrosis remains unclear as well as controversial. A number of animal studies have 
reported profibrotic effects of hypothyroidism (13, 17-21); and beneficial effects of thyroid 
hormone supplementation on fibrosis of the liver (22, 23), heart (24-26), and lung (27). In 
contrast, other animal studies have observed an attenuation of fibrosis in experimental 
hypothyroidism (28, 29), and have shown profibrotic effects of thyroid hormone 
administration (30-34). Similar to animal studies, the results of epidemiological studies are 
also inconsistent. Some studies suggest a link between thyroid function and the risk of 
fibrosis of the liver, heart and lung (12, 14, 15), whereas others report no such association 
(35, 36).  
To date, there is a critical lack of literature synthesis concerning the impact of thyroid 
function on the occurrence and progression of organ fibrosis. Therefore, we aimed to 
summarize the current evidence regarding the association of thyroid function with fibrosis 













































































































































































































MATERIALS AND METHODS 
Data sources and search strategy 
This systematic review was conducted in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-analyses (PRISMA) guidelines for transparent reporting 
(37). The checklist is provided in Appendix 1. Four electronic databases, including Pubmed, 
Medline Ovid, Embase Ovid, and Web-of-Science were searched without language 
restrictions from inception to 14 June 2019, with the help of expert librarians. From the 
date of the last search, we received monthly updates by the medical library in order to 
avoid missing new relevant references. The computer-based searches combined terms 
related to: (I) thyroid function (e.g., thyroid gland, thyroid disease, thyroid function, 
thyroid hormone, thyrotropin, thyroxine, triiodothyronine, thyronine, hyperthyroidism, 
thyrotoxicosis, Graves’, hypothyroidism, Hashimoto, myxedema, deiodinase); (II) fibrosis of 
the liver, heart, and lung (e.g., liver fibrosis, nonalcoholic steatohepatitis, lung fibrosis, 
fibrosing alveolitis, fibrosing interstitial pneumonia, heart fibrosis); and (III) article type 
(i.e., Editorials, letters to the Editor, erratum, conference papers were excluded). Details of 
the search strategy are provided in Appendix 2. 
Study selection and data extraction 
The studies that fulfilled the following criteria were eligible: (I) Observational studies, 
including cross-sectional studies, prospective studies, case-control studies, nested case-
control studies, nested case-cohort studies; (II) Studies that investigated the association of 
hypothyroidism, hyperthyroidism, or thyroid parameters (i.e., thyroid-stimulating 
hormone [TSH], free thyroxine [FT4], free triiodothyronine [FT3]) with fibrosis of the liver, 
heart, or lung, in humans; (III) Studies reporting effect estimates (risk ratio, odds ratio or 
hazard ratio) with 95% confidence intervals (CIs), or correlation coefficients (p-values) used 
to correlate thyroid function with fibrosis, or mean differences (with standard deviations; 
p-values) in thyroid function between cases and controls, or mean differences (with 
standard deviations; p-values) in fibrotic scores between thyroid status categories, or 
prevalence differences (p-values). Case-reports, letters to the editor, proceedings, 
conference abstracts, reviews, systematic reviews, meta-analyses, and animal studies were 












































































































































































































medications on fibrotic diseases were also excluded. There were no restrictions on 
publication year or language.  
Two independent reviewers (AB, SR) screened the titles and abstracts of the citations. The 
full texts of relevant articles were further obtained and independently evaluated. Any 
disagreement between the two reviewers regarding inclusion was resolved through 
consensus or with the help of a third independent reviewer. Full texts and reference lists 
of the selected articles were hand searched to identify additional studies. A predesigned 
data collection form was used to extract relevant information from the selected studies, 
including article source, sample size, demographics of study participants, methods of 
assessing thyroid function and fibrosis, study results and conclusions.  
Quality assessment 
The quality of the included studies was assessed separately by two reviewers (AB, SR) 
using the Newcastle–Ottawa Scale (NOS) for non-randomized studies in meta-analyses 
(Appendix 3a) (38, 39). The quality of cross-sectional studies was assessed by using an 
adapted NOS version (Appendix 3b). NOS evaluates the study quality based on 3 domains, 
namely selection of participants, comparability of study groups, and ascertainment of the 
exposure or outcome of interest. Each study could have a maximum of 9 stars. Based on 
the Agency for Healthcare Research and Quality (AHRQ) standards, the quality of the 
studies was categorized as poor, fair, and good; corresponding to high, moderate, and low 
risk of bias, respectively (Table 4) (38, 40). 
Statistical analyses 
For continuous outcomes, summary measures were presented as mean differences. To 
enhance the comparability among studies, we converted the units of measurements 
where appropriate. We used odds ratios (ORs) with their 95% CIs as provided by the 
included articles, or calculated them manually using available information. Fixed-effects 
Mantel-Haenszel models were used to obtain pooled ORs with 95% CIs for the association 
of hypothyroidism, overt and subclinical hypothyroidism with liver fibrosis (41). We 
constructed forest plots, and assessed heterogeneity by using the I2 statistic, with I2 ≤25% 
considered as low, 25%< I2 <75% as moderate, and I2 ≥75% as high (42). The possibility of 
publication bias was assessed by using funnel plots and Egger regression symmetry tests 












































































































































































































Sensitivity analyses: The following sensitivity analyses were performed: (I) We used 
random-effects models in order to account for heterogeneity. (II) We excluded the studies 
that provided unadjusted estimates, thus limiting the meta-analysis to studies that 
accounted for relevant potential confounders. (III) To assess the impact of individual 
studies on the overall results, we calculated the pooled risk estimates after removing one 
by one the studies from the analyses. (IV) In order to account for a possible influence of 
thyroid medications on our results, the studies on hypothyroidism were stratified in 
studies including or excluding the thyroid medication users. (V) We performed subgroup 
analyses by stage of hypothyroidism (i.e., overt or subclinical hypothyroidism). (VI) The 
studies were stratified based on the source population (non-hospitalized versus 
hospitalized patients). (VII) We performed subgroup analyses by study design (i.e., cross-
sectional or longitudinal studies). 
RESULTS 
Literature search 
The results of the search strategy are presented in Figure 1. After excluding duplicates, we 
identified 2196 relevant citations; and after further screening of abstracts, 63 potentially 
relevant articles were identified. Once the full texts of these articles were examined, 18 
eligible unique studies were selected (12, 14, 15, 35, 36, 44-56). 
Thyroid function and fibrosis of the liver, lung and heart 
Table 1 summarizes the main characteristics of the 18 included studies reporting on the 
association of thyroid function with fibrosis of the liver, lung, and heart. The population 
sample size ranged from 36 to 7259 subjects (Table 1). The median mean age was 51 years 
(range, 36-69), and the median percentage of women was 53 (range, 17-100) (Table 1). Of 
the 18 included studies, 7 studies were performed in Asia (15, 44, 49, 50, 53-55), 6 in the 
United States (14, 35, 45, 46, 48, 51), 3 in Europe (12, 47, 52), 1 in Africa (56) and 1 in 
South America (36) (Table 1). Seventeen studies had a cross-sectional or case-control 
design, and 1 study had a prospective design (Table 1). Ten studies (14, 15, 35, 45, 47-50, 
55, 56) included hospitalized patients, 5 studies recruited participants from outpatient 
clinics (36, 44, 46, 52, 53), and 3 studies included participants from the general population 
(12, 51, 54) (Table 1). All studies controlled for confounders, except for 2 studies that 












































































































































































































The studies reported on blood measurements of thyroid function (TSH, FT4, FT3) (12, 35, 
47, 49, 50, 52, 54-56), overt hypothyroidism (12, 14, 15, 36, 45, 46, 48, 53, 55), subclinical 
hypothyroidism (12, 44, 50, 51, 55, 56), and subclinical hyperthyroidism (12) (Table 2, 
Table 3). Of the 13 studies investigating hypothyroidism, 10 studies did not specify the 
cause of hypothyroidism and 3 studies defined hypothyroidism as Hashimoto`s thyroiditis 
(Table 2). Several definitions of hypothyroidism were used. In 6 studies, the diagnosis of 
hypothyroidism was based on a self-reported disease history and use of thyroid hormone 
replacement therapy (14, 36, 45, 46, 48, 53) (Table 2). Seven studies diagnosed overt and 
subclinical hypothyroidism based on the serum TSH and FT4 measurements, after 
excluding the thyroid medication users (12, 15, 44, 50, 51, 55, 56) (Table 2). Nine studies 
excluded patients with past thyroid surgery (Table 2). 
The outcomes were liver fibrosis (11 studies), myocardial fibrosis (4 studies), and fibrotic 
pulmonary diseases (3 studies) (Table 1). Of the studies assessing liver fibrosis, 7 studies 
used liver biopsy (35, 36, 44-47, 53), 3 studies used fibrosis scores (51, 52, 54), and 2 
studies used liver elastography (12, 52) (Table 1). Myocardial fibrosis was assessed by 
cardiac magnetic resonance imaging, using measurements of myocardial longitudinal 
relaxation time T1-mapping (3 studies) (15, 50, 55), or measurements of late gadolinium 
enhancement (1 study) (49) (Table 1). The fibrotic pulmonary diseases included IPF 
(idiopathic pulmonary fibrosis) (2 studies) (14, 56) and chronic hypersensitivity 
pneumonitis (CHPP) (1 study) (48) (Table 1). IPF and CHPP were diagnosed based on lung 
biopsy and computed tomography, according to the American Thoracic Society criteria (14, 
48, 56) (Table 1).  
The results of studies investigating the association of hypothyroidism with liver fibrosis 
were combined in a meta-analysis. The studies that were included in the meta-analysis 
used logistic regression to evaluate odds ratios. Due to the heterogeneity in methodology 
or differences in the assessment of fibrotic diseases, we could not perform quantitative 
meta-analyses for: (I) studies investigating the association of thyroid parameters with liver 
fibrosis; (II) studies on myocardial fibrosis; and (III) studies on pulmonary fibrosis. 
Liver fibrosis: Eleven studies investigated the association of thyroid status and/or thyroid 
parameters with liver fibrosis (Table 1). Of these, we identified 7 studies investigating the 












































































































































































































54) (Table 3). In the general population, increasing TSH levels were associated with higher 
odds of liver fibrosis (OR, 1.49; CI, 1.04-2.15 per 1 log TSH) (12) (Table 3). In euthyroid 
subjects, some studies reported no association of thyroid function with liver fibrosis (12, 
35, 44, 54) and others reported an association of increasing TSH levels with liver fibrosis 
(47, 51) (Table 3). We also identified one study investigating subclinical hyperthyroidism 
and liver fibrosis, but without finding an association (OR, 0.80; CI, 0.04-3.91) (12). 
Furthermore, we identified studies investigating the association of overt hypothyroidism (5 
studies) (12, 36, 45, 46, 53), and subclinical hypothyroidism (3 studies) (12, 44, 51) with 
liver fibrosis (Table 2). Based on the results of the meta-analysis, the presence of 
hypothyroidism was associated with a higher risk of liver fibrosis compared to 
euthyroidism (pooled OR, 2.48; CI, 1.87-3.29, heterogeneity I2=0%) (Figure 2a). In 
particular, clinical and subclinical hypothyroidism were associated with a higher risk of 
liver fibrosis compared to euthyroidism (pooled OR, 2.82; CI, 1.95-4.07, heterogeneity 
I2=31.4%; pooled OR, 2.12; CI, 1.45-3.12, heterogeneity I2=0%, respectively) (12, 36, 44-46, 
51, 53) (Figure 2b, Figure 2c). Sensitivity analyses using random-effects models provided 
similar estimates (pooled OR for overt hypothyroidism, 2.81; CI, 1.74-4.53; pooled OR for 
subclinical hypothyroidism, 2.12; CI, 1.45-3.12) (Figure 2b, Figure 2c). After sensitivity 
analyses removing one by one the studies from the analyses, the results did not change 
substantially (pooled OR for overt hypothyroidism varying from 2.40 [1.52-3.78] to 3.19 
[2.16-4.70]; pooled OR for subclinical hypothyroidism varying from 2.10 [1.28-3.43] to 2.16 
[1.37-3.41]). After removing the study reporting unadjusted estimates (36), the association 
of overt hypothyroidism with liver fibrosis became stronger and the heterogeneity was 
eliminated (pooled OR, 3.19; CI, 2.16-4.70, heterogeneity I2=0%). The studies that included 
patients with overt hypothyroidism being treated with thyroid hormones (36, 45, 46, 53) 
reported smaller ORs (pooled OR, 2.68; CI, 1.84-3.92) compared to the study that excluded 
thyroid medication users (OR, 6.64; CI, 1.04-23.95) (12). The association of overt 
hypothyroidism with liver fibrosis was stronger in the studies recruiting participants from 
the outpatient clinic or general population (pooled OR, 3.06; CI, 1.56-6.0) (12, 36, 46, 53) 
compared to the study that included hospitalized patients (OR, 2.30; CI, 1.20-4.0) (45). The 












































































































































































































estimates for overt hypothyroidism (pooled OR, 2.68; CI, 1.84-3.92) and subclinical 
hypothyroidism (pooled OR, 2.12; CI, 1.17-4.01).  
Myocardial fibrosis: Four studies investigated the association of hypothyroidism and/or 
thyroid parameters with myocardial fibrosis (15, 49, 50, 55) (Table 1). Of these, 3 studies 
consistently showed that overt and subclinical hypothyroidism are associated with a higher 
degree of diffuse fibrosis than euthyroidism (Table 2) (15, 50, 55). Two studies showed a 
positive correlation of TSH (correlation coefficients varying from 0.49 to 0.52) and a 
negative correlation of FT4 (correlation coefficients -0.48 for both studies) with myocardial 
fibrosis (50, 55), whereas another study did not find an association (49) (Table 3). Three 
studies showed a negative correlation of FT3 with myocardial fibrosis (15, 49, 55) (Table 3). 
Pulmonary fibrosis: Three case-control studies investigated the association of 
hypothyroidism with fibrotic diseases of the lung (14, 48, 56) (Table 2). Overt 
hypothyroidism was associated with a 2.70 and 2.39 times higher odds of IPF and CHPP 
than euthyroidism, respectively, after adjusting for potential confounders as BMI, smoking, 
diabetes, and corticosteroid use (14, 48) (Table 2). Subclinical hypothyroidism was 
associated with a 8.58 times higher odds of IPF than euthyroidism, but the estimate was 
unadjusted for potential confounders (56) (Table 2).  
Quality assessment 
Study bias assessment scores are shown in Table 4. A total of 5 studies scored 5/9 stars, 6 
studies scored 6/9 stars, 5 studies scored 7/9 stars, and 2 studies scored 8/9 stars (Table 
4). Of the 18 included studies, 8 studies were rated as “poor quality”, 6 studies were rated 
as “fair quality”, and 4 studies were rated as “good quality” (Table 4). 
Assessment of publication bias  
The funnel plots for the association of hypothyroidism, overt hypothyroidism, and 
subclinical hypothyroidism with liver fibrosis are shown in Appendix 4. The Egger test did 
not indicate significant funnel plot asymmetry (p-values, 0.9, 0.5, and 0.3, respectively) 
and thus provided no evidence of publication bias, although it should be noted that a 
















































































































































































































This systematic review and meta-analysis summarize the current evidence regarding the 
role of thyroid function on fibrosis of the liver, heart and lung in humans. Overall, low 
thyroid function was associated with increased likelihood of fibrosis of the liver, heart, and 
lung. The association was consistent, irrespective of the diverse study populations, 
methodologies and fibrosis locations. The risk of bias of included studies was low to 
moderate to high. 
Overt hypothyroidism was generally associated with higher likelihood of fibrosis compared 
to subclinical hypothyroidism, suggesting a dose-response relationship. The magnitudes of 
the associations differed across studies, which may be attributable to the differences in 
population characteristics, fibrosis locations, fibrosis assessment, and definitions of 
hypothyroidism used across studies. In general, studies that excluded thyroid medication 
users (12, 44) reported larger effect estimates compared to the studies that included 
hypothyroid patients treated with thyroid hormone replacement therapy (14, 45, 46, 48). 
In the latter group, it is possible that levothyroxine treatment may have reduced the risk of 
fibrosis, further resulting in an underestimation of the observed associations. The 
heterogeneity among studies examining the association of overt hypothyroidism with liver 
fibrosis was eliminated after removing the study by Mazo et al. (36). In this study, the lack 
of adjustment for confounders and the administration of levothyroxine may have led to an 
underestimation of the observed associations (36). Studies examining thyroid parameters 
generally concluded that increasing TSH levels were associated with higher likelihood of 
fibrosis (12, 47, 50). Even in euthyroid subjects, low-normal thyroid function tended to be 
associated with increased likelihood of fibrosis, though sometimes not statistically 
significant (12, 44, 47). This could be explained by insufficient sample sizes or by a lesser 
fibrotic response of low-normal thyroid function compared to low thyroid function. 
The results of this systematic review of observational studies in humans are also supported 
by previous case reports and experimental studies (57-61). Case series and case reports in 
humans have indicated a co-occurrence of hypothyroidism and fibrotic diseases of the 
liver, heart, and lung (57-59). The diffuse myocardial injuries among patients with overt 
hypothyroidism were reversed by restoring euthyroidism with short-term levothyroxine 












































































































































































































suggestive of lung fibrosis were also reversed after receiving thyroid hormone replacement 
therapy (61). Furthermore, several animal studies suggested that fibrosis of the liver, 
heart, and lung, can be promoted by hypothyroidism and can be reversed by the 
administration of thyroid hormones (17, 18, 20, 24, 27, 62).  
Several mechanisms can explain the association of thyroid function with fibrotic diseases, 
including alterations in collagen gene expression, collagen deposition, activity of fibrogenic 
cytokines, and redox balance (13, 19-25, 63). Fibrotic diseases of the liver, heart and lung 
share the common histological feature of extracellular matrix accumulation (64). 
Experimental hypothyroidism can lead to fibrosis via upregulation of the collagen type I 
gene expression (13, 19, 20), whereas thyroid hormone administration reduces collagen 
type I gene expression (22, 24, 25). Thyroid hormones also enhance the matrix 
metalloproteinase activity, further resulting in a collagen breakdown (65). The 
transforming growth factor beta (TGFβ), a potent fibrogenic cytokine, is additionally 
involved in the development of hepatic, myocardial, and pulmonary fibrosis (21, 23, 66, 
67). In hypothyroid patients, TGFβ triggers intracellular changes in SMAD proteins, which 
enter the nucleus, promoting collagen transcription and fibrosis (23). Thyroid hormones, 
on the other hand, antagonize the progression of fibrosis via inhibiting the TGFβ/SMAD-
dependent transcriptional activation (23). Thyroid hormone receptors may play a key role 
in mediating the aforementioned effects of thyroid hormones on hepatic, myocardial, and 
pulmonary fibrosis (13, 23, 27). In experimental studies, thyromimetic compounds 
selective for thyroid hormone receptors have shown antifibrotic properties, whereas 
genetically ablated thyroid hormone receptors resulted in the development of fibrosis (13, 
23, 27). Mitochondrial dysfunction is another mechanism that can explain the link between 
thyroid function and fibrosis (68, 69). Hypothyroidism has been associated with 
mitochondrial dysfunction and increased production of reactive oxygen species, which 
contribute to cell apoptosis and fibrosis (68, 69). This can be opposed by thyroid 
hormones, which improve mitochondrial function and attenuate oxidative stress (68-70). 
Furthermore, it may be speculated that autoimmune processes underlying hypothyroidism 
contribute to the development of fibrosis in the liver, heart and lung. Several studies in this 
systematic review reported that hypothyroid patients with Hashimoto`s thyroiditis had a 












































































































































































































However, none of the studies addressed whether the link between hypothyroidism and 
fibrotic diseases is independent of thyroid peroxidase antibodies or antithyroglobulin 
antibodies. Besides the shared pathways linking thyroid function to fibrosis of the liver, 
heart, and lung, underlying organ-specific mechanisms can play an additional role. For 
example, a hypothyroid state is associated with dyslipidemia, insulin resistance, and 
obesity, which in turn promote the development of liver steatosis that can eventually 
progress to cirrhosis (71-73). Moreover, hypothyroidism-associated lung fibrosis could be 
due to hypoxia, which improves when the hypothyroidism is treated (27). 
One could also hypothesize that health-related problems underlying fibrotic diseases 
affect thyroid parameters. Severe illnesses (e.g., sepsis, hypoxia, chronic illnesses) may 
result in “non-thyroidal illness”, a condition which is characterized by normal or low-
normal serum TSH, low serum FT3 and low serum FT4 levels (74). Although the exact 
mechanisms underlying non-thyroidal illness remain unclear, poor health states can 
stimulate a dysregulation of hypothalamus-pituitary-thyroid axis and alterations in the 
expression of thyroid hormone receptors, transporters or deiodinases, which can 
eventually lead to changes in thyroid hormone levels. The results of this systematic review, 
however, are not likely explained by non-thyroidal illness, because the included studies 
were not performed in critically ill populations. The studies that were performed in 
hospitalized populations usually excluded the patients with chronic and decompensated 
conditions. The other studies were conducted in relatively healthy participants from the 
general population or outpatient clinics.  
To the best of our knowledge, this is the first systematic review, which combines the 
literature regarding the role of thyroid function on fibrosis of the liver, heart and lung, in 
humans. In accordance with the NOS scale, we used strict criteria for the quality 
assessment of the risk of bias. Most of the included studies adjusted for potential 
confounders, including age and sex. Another strength is the consistency of the results in 
the setting of diverse study populations. The wide range of ages (mean age ranging from 
36 to 69) and ethnicities of participants may increase the generalizability of our 
conclusions. Furthermore, we were able to perform summary statistics, and combine the 
available evidence on hypothyroidism and liver fibrosis in a meta-analysis. Sensitivity 












































































































































































































Several limitations of this systematic review warrant consideration. Most of the included 
studies were characterized by a cross-sectional design; therefore, we cannot exclude the 
possibility of reverse causation or bidirectional associations. The results of cross-sectional 
studies in this systematic review, however, were in line with the results of the prospective 
study (12) suggesting a temporal association between low thyroid function and fibrosis 
risk. Additional evidence from experimental studies supports more strongly an effect of 
hypothyroidism on fibrotic diseases rather than vice-versa (17, 18, 20, 24, 27). Another 
limitation of this systematic review is that the included studies used several definitions of 
thyroid dysfunction and different measures of fibrotic outcomes. Nevertheless, results 
were overall consistent. The studies defining thyroid status based on thyroid function 
measurements did not have data available with regard to variations in thyroid function 
over time. Furthermore, the limited number of identified studies illustrates the scarcity of 
evidence on this topic, especially for myocardial and pulmonary fibrosis. 
Future population-based studies examining the association of thyroid dysfunction (i.e., 
hypothyroidism and hyperthyroidism) with the risk of fibrotic diseases should preferably 
be characterized by a prospective design and a long-term follow-up period. Adequately 
powered studies are also needed to clarify whether the risk of fibrosis is affected by the 
fluctuations within the reference range of thyroid function. Of importance, future 
randomized clinical trials are warranted to simultaneously examine the potential beneficial 
effects of thyroid hormone supplementation on fibrosis of the liver, heart and lung. These 
investigations could eventually promote the development of new therapies against fibrotic 
diseases. In addition, thyroid disease may also play a role in the development of other 
fibrotic processes, including idiopathic retroperitoneal fibrosis, primary biliary cirrhosis, 
and skin fibrosis; but the amount of current evidence is very limited and further research is 
needed (23, 75, 76). Given the systemic effects of thyroid hormones, future studies may 
also consider investigating the association of thyroid function with the risk of concomitant 
fibrotic processes in multiple organs. Finally, future observational and experimental 
studies need to provide additional insights on the shared and organ-specific mechanisms 
linking thyroid function to fibrosis of the liver, heart and lung, using mediation analyses 
and interventional approaches. In particular, it remains uncertain whether the link 












































































































































































































hypoxia and chronic illnesses. Given the complexity of the mechanisms underlying fibrosis, 
future studies may need to unravel the interplay of thyroid hormones with inflammatory, 
hormonal, metabolic, immune, environmental, genetic, and other putative risk factors of 
fibrotic diseases.  
Conclusions  
Our findings suggest that low thyroid function is associated with an increased likelihood of 
chronic fibrotic diseases of the liver, heart, and lung, in humans. Results were consistent in 
the setting of diverse study populations. Given the limited amount of prospective evidence 
on this topic, our study highlights the need for future prospective studies and randomized 
clinical trials investigating the potential efficacy of thyroid hormone and its analogues on 
the development of fibrosis. This could eventually lead to the development of novel 
strategies for the prevention and treatment of the fibrotic diseases.  
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Table 1. Description of included studies on the association of thyroid function with 
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*Information is related to the analyses of interest for our particular research question. 
†Stepwise strategy: Sta s cally significant predictors were kept in the model.  #T1-
mapping of the myocardium assesses diffuse myocardial fibrosis. Increased T1-values 
reflect a longer relaxation time and a more advanced stage of diffuse fibrosis. ǂLGE 
imaging is used to assess myocardial fibrosis. Abbreviations: N, total number; USA, United 
States of America; NASH, nonalcoholic steatohepatitis; NAFLD, nonalcoholic fatty liver 
disease; chol, total cholesterol; BMI, body mass index; HOMAIR, insulin resistance; NR, not 
reported; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Tg, 
triglycerides; OH, patients with overt hypothyroidism; MRI, magnetic resonance imaging; 
IDCM, idiopathic dilated cardiomyopathy; LGE, late gadolinium enhancement; SCH, 
patients with subclinical hypothyroidism; IPF, idiopathic pulmonary fibrosis; COPD, chronic 
obstructive pulmonary disease; CS, corticosteroid; CT, computed tomography; CHPP, 












































































































































































































Table 2. Description of studies reporting on the association of hypothyroidism with 

















Liver fibrosis  OR (CI)
Liangpunsaku
l, 2003 (45) 
Overt  NS Previous 
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Liu M, 2019 
(55) 

























Overt NS Use of THR, no 
thyroid 
surgery 






































































































































































































































40.18)   
*Thyroid status categories were defined based on TSH (thyroid-stimulating hormone) and 
FT4 (free thyroxine) measurements. Subclinical hypothyroidism was diagnosed as increased 
serum TSH levels and normal serum FT4 levels. Clinical hypothyroidism was diagnosed as 
increased serum TSH levels and decreased serum FT4 levels. †Thyroid function was 
categorized into strict-normal (TSH 0.4-2.5 mIU/L) (reference), low-normal (TSH 2.5-4.5 
mIU/L), and subclinical hypothyroidism (TSH >4.5 mIU/L). # Indicates mean difference (95% 
confidence interval) in T1 values between hypothyroid patients and euthyroid subjects. T1-
mapping of the myocardium assesses diffuse myocardial fibrosis. Increased T1-values 
reflect a longer relaxation time and a more advanced stage of diffuse fibrosis. ⁑Cases had 
posi ve thyroid peroxidase an bodies. ‡Cases had posi ve thyroid peroxidase an bodies 
and positive antithyroglobulin antibodies. Abbreviations: OR, odds ratio; CI, 95% 
confidence interval; NS, not specified; THR, thyroid hormone replacement therapy; NASH, 
nonalcoholic steatohepatitis; ms, milliseconds; T1, myocardial longitudinal relaxation time; 
T1-LVAW, T1-left ventricular anterior wall; T1-IVS, T1-interventricular septum; T1-LVIW, 
T1-left ventricular inferior wall; T1-LVLW, T1-left ventricular lateral wall; T1-LV, left 
ventricular myocardial T1; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive 












































































































































































































Table 3. Description of studies reporting on the association of thyroid parameters (TSH, 

















OR (CI), 2.74 
(1.15; 6.53) per 
1 mU/L 
  
   MD (CI), 0.54 
(0.13; 0.94)  
mU/L 
MD (CI), 0.05 
(-0.04; 0.14) 
ng/dl 










OR (CI), 1.49 
(1.04; 2.15) per 
1 logTSH 
OR (CI), 0.59 
(0.13; 2.59) 
per 1 ng/dl 
 
 Euthyroid  OR (CI), 1.13 
(0.63; 2.03) 

































































































































































































































































0.10)  ng/dl† 
MD (CI), 0.13 
(0.01; 0.25) 
pmol/l 
OR (CI), 1.18 









MD (CI), 0.26 (-
0.26; 0.78) 
mU/L 
 MD (CI), -0.84 (-
1.28; -0.39) 
pmol/l# 
OR (CI), 0.32 

















OR (CI), 0.98 
(0.93; 1.04) per 
1 mU/L logTSH 
OR (CI), 0.37 
(0.05; 2.75) 
per 1 ng/dl 
OR (CI), 0.28 








r, 0.49 (p, 
0.002) 
r, -0.48 (p, 
0.003) 
 


































































































































































































































MD (CI), 0.74 
(0.21; 1.27) 
mU/L 




a The effect estimates in this table are presented as: (I) odds ratio for the association of 
thyroid parameters with fibrosis; (II) mean difference in thyroid parameters between cases 
and controls; (III) correlation coefficient used to correlate thyroid parameters with T1-
mapping; and (IV) prevalence of fibrotic disease throughout the range of thyroid 
parameters. b The reported estimates correspond to the euthyroid range or the full range 
of thyroid function. c Thyroid function was categorized into strict-normal (TSH 0.4-2.5 
mIU/L) (reference), low-normal (TSH 2.5-4.5 mIU/L), and subclinical hypothyroidism (TSH 
>4.5 mIU/L). d T1-mapping of the myocardium assesses diffuse myocardial fibrosis. 
Increased T1-values reflect a longer relaxation time and a more advanced stage of diffuse 
fibrosis. e LGE imaging is used to assess myocardial fibrosis. *Converted from pg/ml. 
†Converted from pmol/l. #Converted from ng/l. Abbreviations: TSH, thyroid-stimulating 
hormone; FT4, free thyroxine; FT3, free triiodothyronine; NASH, nonalcoholic 
steatohepatitis; OR, odds ratio; CI, 95% confidence interval; MD, mean difference; NAFLD, 
non-alcoholic fatty liver disease; LGE, late gadolinium enhancement; r, correlation 












































































































































































































Table 4. Quality Assessment Scale



















*** ** * 6/9 Poor 
Mazo, 2011 (36) ***  *** 6/9 Poor 
Pagadala, 2012 (46) * ** *** 6/9 Poor 
Carulli, 2013 (47) ** ** *** 7/9 Fair 
Parikh, 2015 (53) *** ** *** 8/9 Good 
Bano, 2016 (12) **** ** ** 8/9 Good 
Bril, 2016 (35) **  *** 5/9 Poor 
Kim, Kim, 2018 (44) ** ** *** 7/9 Fair 
Kim, Yoo, 2019 (51) *** ** ** 7/9 Good 
Liu Y, 2018 (54) *** ** ** 7/9 Good 
Manka, 2019 (52) ** * ** 5/9 Fair 
Gao, 2016 (15) * * *** 5/9 Poor
Wang, 2016 (49) * ** *** 6/9 Poor
Yao, 2018 (50) ** * *** 6/9 Fair 
Liu M, 2019 (55) ** * *** 6/9 Fair 
Oldham, 2015 (14) ** ** * 5/9 Poor 
Adegunsoye, 2017 
(48) 
* ** ** 5/9 Poor   
Aboelnaga, 2019 
(56) 
** ** ** 6/9 Fair 
†The thresholds for converting the Newcastle-Ottawa Scale (NOS) scores into the Agency 
for Healthcare Research and Quality (AHRQ) standards were: (I) Good quality: 3 or 4 stars 
in the selection domain AND 1 or 2 stars in the comparability domain AND 2 or 3 stars in 













































































































































































































stars in the comparability domain AND 2 or 3 stars in the exposure/outcome domain. (III) 
Poor quality: 0 or 1 star in the selection domain OR 0 star in the comparability domain OR 





















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Forest plots for the association of hypothyroidism with liver fibrosis. a. Overt 
and subclinical hypothyroidism; b. Overt hypothyroidism; c. Subclinical hypothyroidism. 
Abbreviations: OR, odds ratio; CI, confidence interval; I-V, inverse variance (fixed) method; 














































































































































































































Appendix 1. PRISMA 2009 checklist.
Section/Topic Checklist item  Page 
TITLE 
Title  1 Identify the report as a 
systematic review, meta-





2 Provide a structured 
summary including, as 
applicable: background; 
objectives; data sources; 
study eligibility criteria, 
participants, and 
interventions; study 
appraisal and synthesis 
methods; results; 
limitations; conclusions and 
implications of key findings; 
systematic review 
registration number.  
3-4 
INTRODUCTION  
Rationale  3 Describe the rationale for 
the review in the context of 
what is already known.  
5
Objectives  4 Provide an explicit 
statement of questions 
being addressed with 



















































































































































































































5 Indicate if a review protocol 
exists, if and where it can 
be accessed (e.g., Web 
address), and, if available, 
provide registration 
information including 







6 Specify study characteristics 
(e.g., PICOS, length of 
follow-up) and report 
characteristics (e.g., years 
considered, language, 
publication status) used as 





7 Describe all information 
sources (e.g., databases 
with dates of coverage, 
contact with study authors 
to identify additional 
studies) in the search and 
date last searched.  
6-7 
Search  8 Present full electronic 
search strategy for at least 
one database, including any 
limits used, such that it 















































































































































































































9 State the process for 
selecting studies (i.e., 
screening, eligibility, 
included in systematic 
review, and, if applicable, 






10 Describe method of data 
extraction from reports 
(e.g., piloted forms, 
independently, in duplicate) 
and any processes for 
obtaining and confirming 
data from investigators.  
7 
Data items  11 List and define all variables 
for which data were sought 
(e.g., PICOS, funding 
sources) and any 
assumptions and 
simplifications made.  
7, Appendix 2 
Risk of bias in 
individual 
studies  
12 Describe methods used for 
assessing risk of bias of 
individual studies (including 
specification of whether 
this was done at the study 
or outcome level), and how 
this information is to be 
used in any data synthesis.  
8, Appendix 3, Appendix 4 
Summary 
measures  
13 State the principal summary 














































































































































































































difference in means).  
Synthesis of 
results  
14 Describe the methods of 
handling data and 
combining results of 
studies, if done, including 
measures of consistency 














































































































































































































Appendix 1 (continued). PRISMA 2009 Checklist. 
Section/Topic Checklist item Page 
METHODS 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 






16 Describe methods of additional analyses (e.g., sensitivity 
or subgroup analyses, meta-regression), if done, 





17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 





18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
9, Table 
1 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 






20 For all outcomes considered (benefits or harms), present, 
for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence 




21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
11-12, 
Figure 2 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 






23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression [see 


















































































































































































































24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
13 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk 
of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
17 
Conclusions  26 Provide a general interpretation of the results in the 




Funding  27 Describe sources of funding for the systematic review 
and other support (e.g., supply of data); role of funders 
for the systematic review.  
18 
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 













































































































































































































Appendix 2. Supplemental information on Search strategy 
Search in Pubmed 
(((Thyroid*[Title/Abstract] OR hyperthyro*[Title/Abstract] OR Hypothyro* [Title/Abstract] 
OR thyronine* [Title/Abstract] OR Hashimoto[Title/Abstract] OR thyroid-stimulating 
hormone [Title/Abstract] OR “free thyroxine”[Title/Abstract] OR Graves[Title/Abstract] OR 
thyrotropin[Title/Abstract] OR deiodinase[Title/Abstract] OR 
triiodothyronine[Title/Abstract] OR myxedema[Title/Abstract]  OR 
thyrotoxicosis[Title/Abstract] OR hyperthyroxinemia [Title/Abstract])) AND 
(Fibrosis[Title/Abstract] OR fibrotic[Title/Abstract] OR fibrosing[Title/Abstract] OR 
fibroblast[Title/Abstract] OR “non-alcoholic steatohepatitis”[Title/Abstract] OR 
“nonalcoholic steatohepatitis”[Title/Abstract])) AND (Heart [Title/Abstract] or cardiac 
[Title/Abstract] or cardiovascular[Title/Abstract]  or lung [Title/Abstract] or pulmonary 
[Title/Abstract] or liver [Title/Abstract] or hepatic[Title/Abstract] or endocardium 
[Title/Abstract] or myocardium [Title/Abstract] or pericardium[Title/Abstract]) 
Search in Medline Ovid 
((exp thyroid gland/ or hyperthyroxinemia/ or hyperthyroidism/ or hypothyroidism/ or 
thyroid function tests/ 
or thyroxine/ or thyroid hormones/ or thyrotropin/ or thyroxine/) OR (Thyroid* or 
hyperthyro* or Hypothyro* or free thyroxine or thyroid-stimulating hormone  or Graves or  
thyrotropin or thyroxin or deiodinase or hashimoto or triiodothyronine or thyronine* or 
myxedema or thyrotoxicosis or hyperthyroxinemia).ab,ti.) AND ((Fibrotic or fibrosis or non-
alcoholic steatohepatitis or nonalcoholic steatohepatitis or fibrosing).ab,ti.  OR 
fibroblast.mp or fibrosis/ or exp pulmonary fibrosis/ or exp endomyocardial fibrosis/ or 
idiopathic pulmonary fibrosis/) AND (Heart or cardiac or endocardium or myocardium or 
pericardium or lung or pulmonary or liver or hepatic  or cardiovascular).ab,ti. NOT 
(congress or editorial or guideline or letter or news or Published Erratum or conference or 
comment).pt.       
Search in Embase Ovid 













































































































































































































or thyrotropin/  or thyroxine/ or exp thyroid hormone blood level/ or exp thyroid gland 
examination/) or (Thyroid* or hyperthyro* or Hypothyro* or free thyroxine or Graves or 
thyrotropin or thyroxin or deiodinase or hashimoto or triiodothyronine or thyronine* or 
myxedema or thyrotoxicosis or hyperthyroxinemia).ab,ti. ) AND ((Fibrotic or fibrosis or 
non-alcoholic steatohepatitis or nonalcoholic steatohepatitis or fibroblast).ab,ti.  Or (exp 
fibrosing alveolitis/ or exp fibrosing interstitial pneumonia/ or exp heart muscle fibrosis/ or 
exp liver fibrosis/ or exp lung fibrosis/)) AND ((Heart or cardiac or endocardium or 
myocardium or pericardium or lung or pulmonary or liver or hepatic or 
cardiovascular).ab,ti.) NOT (Editorial or Letter or Note or Erratum or Conference Paper or 
Conference Abstract or Conference Review).pt. 
Search in Web-of-Science 
(TS=(Thyroid* or hyperthyro* or Hypothyro* or “free thyroxine” or thyroid-stimulating 
hormone or Graves or thyrotropin or deiodinase or triiodothyronine or myxedema or 
thyrotoxicosis or hyperthyroxinemia or thyronine* or hashimoto)) AND (TS=(Fibrosis or 
fibrotic or fibroblast or non-alcoholic steatohepatitis or nonalcoholic steatohepatitis or 
fibrosing)) AND (TS=(Heart OR cardiovascular or cardiac OR endocardium OR myocardium 
OR pericardium OR lung or pulmonary OR liver OR hepatic)) AND DOCUMENT TYPES: 
(Article) 
Appendix 3. Quality Assessment Scale for included studies 
Appendix 3a. Newcastle-Ottawa Quality Assessment Scale for case-control studies 
Selection (max 4 stars) 
1) Is the case definition adequate? 
a. yes, with independent validation* 
b. yes, eg, record linkage or based on self-reports 
c. no description 
2) Representativeness of the cases 
a. consecutive or obviously representative series of cases* 
b. potential for selection biases or not stated 
3) Selection of controls 
a. community controls* 












































































































































































































c. no description 
4) Definition of controls 
a. no history of disease (end point)* 
b. no description of source 
Comparability (max 2 stars) 
1) Comparability of cases and controls on the basis of the design or analysis 
a. study controls for the most important factors* 
b. study controls for any additional factor** 
Exposure (max 3 stars) 
1) Ascertainment of the exposure 
a. secure record (eg, surgical records)* 
b. structured interview where blind to case/control status* 
c. interview not blinded to case/control status 
d. written self-report or medical record only 
e. no description 
2) Same method of ascertainment for cases and controls 
a. yes* 
b. no 
3) Non-response rate 
a. same rate for both groups* 
b. non-respondents described 
c. rate different and no designation 
Appendix 3b. Adapted Scale from the Newcastle-Ottawa Quality Assessment Scale for 
cohort studies  
Selection (max 4 stars) 
1) Representativeness of the exposed cohort 
a. Truly representative of the average in the  target population (all subjects or 
random sampling)* 
b. Somewhat representative of the average in the target population (non-
random sampling)* 












































































































































































































d. No description of the derivation of the cohort 
2) Sample size 
a. Justified and satisfactory* 
b. Not satisfied 
3) Ascertainment of the exposure (risk factor) 
a. Secure record (eg, medical records)* 
b. Structured interview* 
c. Written self-report 
d. No description of the measurement tool 
4) Non-respondents 
a. Comparability between respondents and non-respondents characteristics is 
established, and the response rate is satisfactory* 
b. The response rate is unsatisfactory, or the comparability between 
respondents and non-respondents is unsatisfactory 
c. No description of the response rate or the characteristics of the 
respondents and the non-respondents 
Comparability (max 2 stars) 
1) The subjects in the different outcome groups are comparable, based on the study 
design or analysis. Confounding factors are controlled. 
a. Study controls for the most important factors (age, sex)* 
b. Study controls for additional relevant factors** 
c. Inadequate degree of control 
Outcome (max 3 stars) 
1) Assessment of the outcome 
a. Independent or blind assessment stated in the paper, or confirmation of the 
outcome by reference to secure records (eg, X-rays, medical records)** 
b. Record linkage (eg, identified through ICD codes on database records)** 
c. Self-report (ie, no reference to original medical records or X-rays to confirm 
the outcome)* 













































































































































































































2) Statistical test 
a. The statistical test used to analyze the data is clearly described and 
appropriate, and the measurement of the association is presented, 
including the probability level (p-value)* 





























































































































































































Appendix 4. Funnel plots on the association of hypothyroidism with liver fibrosis. The log odds ratios (ORs) are plotted against the standard 
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